Tricyclic compounds and compositions as kinase inhibitors

A compound of formula (A):

• in which:
• R′ is selected from the group consisting of H and methyl;
• R1 is C1-3alkyl substituted by CN or by one or more halogens;
• R2 is selected from the group consisting of:
• wherein Z1 is CR3R4, —O—, a bond, or CR7;
• provided that when Z1 is CR7, Z1 is attached to the carbon atom bonded to R9 by a double bond and R9 is absent;
• Z2 is CR5R6, O, —C(O)NR8—[Y6], —NR8C(O)—[Y6], or —(CR7)0-1—C(O)—[Y6], where [Y6] indicates which atom of Z2 is attached to the ring containing Y6;
• provided Z1 and Z2 are not both simultaneously O;
• Z3 is a carbon atom bonded to Y6 by an aromatic bond, or Z3 is a nitrogen atom bonded to Y6 by a single bond;
• R3 is selected from the group consisting of hydrogen, C1-3alkyl, halo, C1-3alkyl-amino-carbonyl, C1-3alkyl-S(O)0-2—C1-2alkyl, carboxyl and hydroxy-substituted-C1-3alkyl;
• R4 is selected from the group consisting of hydrogen, amino, C1-3alkyl, cyano, hydroxy-ethyl and halo;
• or R3 and R4 together with the carbon atom to which R3 and R4 are attached form a 4 member saturated cyclic ring containing an oxygen molecule;
• R5 is selected from the group consisting of hydrogen, halo, amino, C1-3alkyl-amino-carbonyl, C1-3alkyl-carbonyl, hydroxy and C1-3alkoxy;
• R6 is selected from the group consisting of hydrogen, C1-3alkyl, halo, halo-substituted-C1-3alkyl;
• or R4 and R6 together with the carbon atom to which R4 and R6 are attached form 5-6 member unsaturated ring containing up to 2 heteroatoms selected from O, S and N;
• wherein said ring is optionally substituted with C1-2alkyl;
• R7 is selected from the group consisting of hydrogen, hydroxy-carbonyl and C1-3alkoxy-carbonyl;
• R8 is selected from the group consisting of hydrogen, C1-3alkyl-amino-carbonyl, C1-3alkyl-carbonyl, C1-3alkoxy and hydroxy-substituted-C1-4alkoxy, hydroxy-substituted-C1-3alkyl, and C1-3alkyl;
• R9 is independently selected at each occurrence from the group consisting of hydrogen, fluorine, and methyl;
• each R10 represents an optional substituent selected from the group consisting of C1-3 alkyl and C1-3 alkoxy, or two R10 on non-adjacent ring atoms can be taken together to form a bond or a (CH2)1-2 bridge linking the two non-adjacent ring atoms to form a fused or bridged ring;
• Y0 is selected from the group consisting of N, CH and CF;
• Y1 is selected from the group consisting of N and CH;
• Y2 is selected from the group consisting of N, CH, CF, CCl, C—NH2, and C—C(R9)2NH2;
• Y3 is selected from the group consisting of N and CH;
• Y4 is selected from the group consisting of N and CH;
• Y5 is selected from the group consisting of N and CH;
• and
• Y6 is selected from the group consisting of N and CH when Z3 is carbon, and Y6 is C(═O) when Z3 is nitrogen;
• or a pharmaceutically acceptable salt thereof.